BACKGROUND: Activating somatic mutations in the promoter region of the telomerase reverse transcriptase gene (TERT) have been detected in several cancers. In this study we investigated the TERT promoter mutations and their impact on patient survival in World Health Organization grade IV glioblastoma multiforme (GBM). METHODS: The TERT core promoter region containing the previously described mutations and a common functional polymorphism (rs2853669) was sequenced in tumors and blood samples from 192 GBM patients. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status was assessed by pyrosequencing in 177 (92.2%) cases. Relevant clinical data were obtained from a prospectively maintained electronic database. RESULTS: We detected specific (-124 C>T and -146 C>T) TERT promoter mutations in 143/178 (80.3%) primary GBM and 4/14 (28.6%) secondary GBM (P < .001). The presence of TERT mutations was associated with poor overall survival, and the effect was confined to the patients who did not carry the variant G-allele for the rs2853669 polymorphism. An exploratory analysis suggested that TERT mutations might be prognostic only in patients who had incomplete resections and no temozolomide chemotherapy. CONCLUSIONS: In this study, specific TERT promoter mutations were markers of primary GBM and predicted patient survival in conjunction with a common functional polymorphism. The prognostic impact of TERT mutations was absent in patients with complete resections and temozolomide chemotherapy. If confirmed in additional studies, these findings may have clinical implications, that is, TERT mutations appear to characterize tumors that require aggressive treatment.
BACKGROUND: Activating somatic mutations in the promoter region of the telomerase reverse transcriptase gene (TERT) have been detected in several cancers. In this study we investigated the TERT promoter mutations and their impact on patient survival in World Health Organization grade IV glioblastoma multiforme (GBM). METHODS: The TERT core promoter region containing the previously described mutations and a common functional polymorphism (rs2853669) was sequenced in tumors and blood samples from 192 GBM patients. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status was assessed by pyrosequencing in 177 (92.2%) cases. Relevant clinical data were obtained from a prospectively maintained electronic database. RESULTS: We detected specific (-124 C>T and -146 C>T) TERT promoter mutations in 143/178 (80.3%) primary GBM and 4/14 (28.6%) secondary GBM (P < .001). The presence of TERT mutations was associated with poor overall survival, and the effect was confined to the patients who did not carry the variant G-allele for the rs2853669 polymorphism. An exploratory analysis suggested that TERT mutations might be prognostic only in patients who had incomplete resections and no temozolomide chemotherapy. CONCLUSIONS: In this study, specific TERT promoter mutations were markers of primary GBM and predicted patient survival in conjunction with a common functional polymorphism. The prognostic impact of TERT mutations was absent in patients with complete resections and temozolomide chemotherapy. If confirmed in additional studies, these findings may have clinical implications, that is, TERT mutations appear to characterize tumors that require aggressive treatment.
Authors: João Vinagre; Ana Almeida; Helena Pópulo; Rui Batista; Joana Lyra; Vasco Pinto; Ricardo Coelho; Ricardo Celestino; Hugo Prazeres; Luis Lima; Miguel Melo; Adriana Gaspar da Rocha; Ana Preto; Patrícia Castro; Ligia Castro; Fernando Pardal; José Manuel Lopes; Lúcio Lara Santos; Rui Manuel Reis; José Cameselle-Teijeiro; Manuel Sobrinho-Simões; Jorge Lima; Valdemar Máximo; Paula Soares Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: L Boldrini; S Pistolesi; S Gisfredi; S Ursino; G Ali; N Pieracci; F Basolo; G Parenti; G Fontanini Journal: Int J Oncol Date: 2006-06 Impact factor: 5.650
Authors: P Sivaramakrishna Rachakonda; Ismail Hosen; Petra J de Verdier; Mahdi Fallah; Barbara Heidenreich; Charlotta Ryk; N Peter Wiklund; Gunnar Steineck; Dirk Schadendorf; Kari Hemminki; Rajiv Kumar Journal: Proc Natl Acad Sci U S A Date: 2013-10-07 Impact factor: 11.205
Authors: Christian Hartmann; Bettina Hentschel; Matthias Simon; Manfred Westphal; Gabriele Schackert; Jörg C Tonn; Markus Loeffler; Guido Reifenberger; Torsten Pietsch; Andreas von Deimling; Michael Weller Journal: Clin Cancer Res Date: 2013-08-05 Impact factor: 13.801
Authors: Jozefina Casuscelli; Maria F Becerra; Brandon J Manley; Emily C Zabor; Ed Reznik; Almedina Redzematovic; Maria E Arcila; Daniel M Tennenbaum; Mazyar Ghanaat; Mahyar Kashan; Christian G Stief; Maria Carlo; Martin H Voss; Darren R Feldman; Robert J Motzer; Yingbei Chen; Victor E Reuter; Jonathan A Coleman; Paul Russo; James J Hsieh; Abraham Ari Hakimi Journal: Eur Urol Focus Date: 2017-09-24
Authors: Pablo Tamayo; Thomas R Cech; Franklin W Huang; Josh Lewis Stern; Grace Hibshman; Kevin Hu; Sarah E Ferrara; James C Costello; William Kim Journal: Mol Cancer Res Date: 2020-04-10 Impact factor: 5.852
Authors: Armita Bahrami; Seungjae Lee; Inga-Marie Schaefer; Jennifer M Boland; Kurt T Patton; Stanley Pounds; Christopher D Fletcher Journal: Mod Pathol Date: 2016-08-26 Impact factor: 7.842